ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Outcome of Systemic Monitoring of DSA and Protocol Management to Optimize Renal Allograft Outcome in a Single Transplant Center.

S. Chang,1 I. Mallawaarachchi,2 C. Yip,1 T. Shanahan,3 A. Gundroo,1 A. Dwivedi,2 S. Patel,4 M. Zachariah.1

1Internal Medicine, University of Buffalo, Buffalo, NY
2Biomedical Sciences, Texas Tech University, El Paso, TX
3IMMCO Diagnostics, Buffalo, NY
4Surgery, University of Buffalo, Buffalo, NY

Meeting: 2017 American Transplant Congress

Abstract number: B69

Keywords: Graft function, HLA antibodies, HLA matching, Kidney/pancreas transplantation

Session Information

Session Name: Poster Session B: Antibody Mediated Rejection in Kidney Transplant Recipients II

Session Type: Poster Session

Date: Sunday, April 30, 2017

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall D1

Denovo (dn) donor specific antibody (DSA) development has been shown to adversely affect long-term allograft survival. To improve graft outcome for kidney (K) transplant (Tx) recipients, ECMC has taken aggressive approach to systemic screening DSA post-Tx. Method: A single center retrospective study at Univ. of Buffalo from Jan 2012 to Sept 2016 included 379 K Tx recipients, PTA were excluded. Induction was with Thymoglobulin, maintenance with Pred, Tac, & MMF. DSA monitoring at 1 month (m), 2 m, 3 m, 6 m, yearly interval, more frequently if DSA positive. Management of + DSA includes Tx K Bx if MFI>3000, & treatment depends on the bx finding. ACR is treated with steroid bolus, acute AMR with steroid bolus ± thymoglobulin & plasmapheresis & IVIG. Patients (pt) without rejection were treated with IVIG (2 grams/kg) & close DSA monitor until negative (MFI<1500). Results: 49 recipients developed dn DSA, and 330 did not. Of those with DSA, 57% were females, 27% developed HLA I DSA, 88% had HLA II DSA, 12% had both HLA I & II DSA. Median onset for HLA I DSA occurred at 40 days (range 15-642 days) post-tx, & HLA II DSA at 180 days (11-1367 days, p<0.05). Denovo HLA II DSA occurred more frequently, with more DR, DRw, and DQ mismatches. Of those who had bx (N=45), 36% had ACR, 20% AMR, 15% both ACR + AMR & was more likely to have both HLA I & II DSA. 9 pts had graft failure, median time 2.5 yrs post-tx, all had HLA II DSA. No differences in eGFR was found in pts with HLA I vs. II DSA. Pts with higher cPRA developed more HLA I vs. HLA II DSA (p<0.02). Comparing pts who developed dn DSA vs. who did not, recipients with DSA have higher cPRA (p<0.001), & lower EPTS (p<0.02). Serum Cr in pts without DSA were lower at 1 month, & 1 yr (p=0.01, p=0.05), but no different at 2 yr & 3 yr when compared to pts with DSA. Conclusion: 12.9% Tx K recipients develop dn DSA, at earlier post-tx period with Class I HLA, more frequently later with Class II HLA. Pts with more mismatches in the DR, DRw, & DQ tend to develop HLA II DSA. Recipients who are more sensitized, at younger age were likely to develop dn DSA post-tx, have higher serum Cr at 1 month & 1 yr, but no longer different at 2 & 3 yrs with aggressive DSA management.

CITATION INFORMATION: Chang S, Mallawaarachchi I, Yip C, Shanahan T, Gundroo A, Dwivedi A, Patel S, Zachariah M. Outcome of Systemic Monitoring of DSA and Protocol Management to Optimize Renal Allograft Outcome in a Single Transplant Center. Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Chang S, Mallawaarachchi I, Yip C, Shanahan T, Gundroo A, Dwivedi A, Patel S, Zachariah M. Outcome of Systemic Monitoring of DSA and Protocol Management to Optimize Renal Allograft Outcome in a Single Transplant Center. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/outcome-of-systemic-monitoring-of-dsa-and-protocol-management-to-optimize-renal-allograft-outcome-in-a-single-transplant-center/. Accessed May 8, 2025.

« Back to 2017 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences